Who is eligible for dengue vaccination and what is the recommended dosing schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Dengue Vaccine Eligibility and Dosing

Dengvaxia is recommended for children aged 9-16 years with laboratory-confirmed prior dengue infection living in dengue-endemic areas of the United States and its territories (Puerto Rico, American Samoa, U.S. Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, and Republic of Palau). 1

Eligibility Criteria

Age Requirements

  • 9-16 years old (children and adolescents only) 1
  • This vaccine is NOT approved for adults or children outside this age range in the United States

Critical Pre-Vaccination Requirement

Laboratory confirmation of previous dengue infection is mandatory before vaccination. 1 This requires:

  • Detection of anti-DENV immunoglobulin G using a highly specific serodiagnostic test
  • Documentation must be obtained BEFORE administering any vaccine dose

Geographic Eligibility

Must be living in U.S. dengue-endemic areas:

  • Puerto Rico
  • American Samoa
  • U.S. Virgin Islands
  • Federated States of Micronesia
  • Republic of Marshall Islands
  • Republic of Palau 1

Dosing Schedule

The vaccine (Dengvaxia/CYD-TDV) is administered as:

  • 3-dose series 2
  • Doses given at 0,6, and 12 months 2
  • Each dose is 0.5 mL administered subcutaneously

Critical Safety Consideration

The requirement for prior dengue infection is non-negotiable. Dengvaxia increases the risk of severe dengue in individuals who receive the vaccine and then experience their first natural dengue infection (primary infection) after vaccination. 1 This phenomenon is related to antibody-dependent enhancement (ADE). 3

Common Pitfall to Avoid

Do not vaccinate based on:

  • Living in an endemic area alone
  • Travel history to endemic regions
  • Clinical suspicion of prior infection without laboratory confirmation
  • Patient or parent report of prior dengue illness without serologic proof

Without documented prior infection, vaccination is contraindicated regardless of exposure risk or travel plans.

Additional Contraindications

As a live-attenuated vaccine, Dengvaxia is contraindicated in:

  • Immunocompromised individuals 3
  • Pregnant women 3
  • Individuals outside the 9-16 year age range (per U.S. FDA licensing) 1

The vaccine's mechanism involves a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone, providing protection against all four dengue serotypes (DENV-1-4). 1

References

1
Research

Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 2021

Related Questions

Can the Qdenga (dengue vaccine) be administered to individuals who are dengue seropositive?
What is the recommended dengue vaccine and its administration schedule?
What are the Philippine clinical practice guidelines for diagnosing and managing dengue infection?
Can a dengue-positive mother safely breastfeed her 5-month-old infant?
Who is eligible for the dengue vaccine and what are the contraindications?
What is the appropriate management for a serum lithium level of 1.5 mEq/L?
Can an MRI be performed while temporary epicardial pacing wires placed after coronary artery bypass grafting are still in place?
What is the maximum storage duration for a reconstituted intravenous admixture before administration?
What are the appropriate treatment options and dosing regimens for urinary tract infection?
What is the recommended treatment for a left knee oblique tear of the medial meniscus involving the body and posterior horn free margin, mild patellofemoral chondromalacia, and trace joint effusion?
Is it appropriate to administer oral ketorolac together with a narcotic for pain management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.